View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Carole Braudeau
  • Carole Braudeau

Credit Morning 05/17/2024

Cellnex issues € 750m of 2029 notes to redeem bank debt. S&P cuts the rating of ams OSRAM to B/stable from BB-/negative. Clariane : launch of two capital increases totalling €328m, including one reserved for HLD Europe. >...

Carole Braudeau
  • Carole Braudeau

Morning Crédit 17/05/2024

Cellnex émet 750 m EUR d’obligations 01/2029 afin de rembourser de la dette bancaire. S&P dégrade le rating d’ams OSRAM de BB-/négative à B/stable. Clariane : lancement de deux augmentations de capital d’un montant total de 328 m EUR, dont une réservée à HLD Europe. >...

 PRESS RELEASE

Genmab to Present New and Updated Results From Multiple Clinical Trial...

Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress Media ReleaseCOPENHAGEN, Denmark; May 14, 2024 Sixteen abstracts accepted for presentation and publication demonstrate depth and breadth of comprehensive epcoritamab development programThree oral presentations highlight novel data evaluating epcoritamab in patients with relapsed/refractory (R/R) follicular lymphoma (FL), in combination for first-line treatment of diffuse large B-cell lymphoma (DLBCL),...

Fresenius SE & Co. KGaA: Key facts and statistics - 2023

A summary company profile, detailing Fresenius SE & Co. KGaA’s business operations and financial highlights.

Carole Braudeau
  • Carole Braudeau

Credit Morning 05/14/2024

Iliad prices € 150m and $ 200m taps on the new Iliad Holding 2031 bonds Grifols: S&P confirms the B corporate rating with a stable outlook (vs. B/cw negative) Delivery Hero: sale of foodpanda to Uber for $ 950m + capital increase of € 300m>...

Michael B. Schäfer ... (+2)
  • Michael B. Schäfer
  • Stephan Wulf

Bayer : FY guidance confirmed after solid Q1 results – Pharma better, ...

>EBITDA decline less pronounced than feared - At a group level, Bayer’s Q1 sales of € 13.8bn (-4.3%), was below our (€ 14.0bn) and the consensus estimates (€ 14.1bn), the group’s EBITDA of € 4,412m (-1.3%) came in stronger than we expected (€ 4,188m) and was 6.4% above the consensus. The group’s EBITDA decline vs Q1 2023 was driven by the Crop Science divisions, where a decrease in glyphosate-based herbicides and cost inflation weighed on earnings. On the back of the ...

Carole Braudeau
  • Carole Braudeau

Morning Crédit 14/05/2024

Iliad abonde les obligations Iliad Holding 2031 à hauteur de 150 m EUR et 200 m USD Grifols : S&P confirme le rating corporate B avec une perspective stable (vs. B/cw negative) Delivery Hero : cession de foodpanda à Uber pour 950 m USD + augmentation de capital réservée de 300 m USD>...

Jamila El Bougrini ... (+2)
  • Jamila El Bougrini
  • Thibaut Voglimacci-Stephanopoli
Rafael Bonardell
  • Rafael Bonardell

BAYER: RDOS. 1T’24 (ANÁLISIS BANCO SABADELL)

Rdos. 1T'24 vs 1T'23: Ventas: 13.765 M euros (-4,3% vs -3,2% BS(e) y -2,1% consenso); EBITDA: 4.412 M euros (-1,3% vs -10,6% BS(e) y -7,2% consenso).

Research Department
  • Research Department

INFORME DIARIO 14 MAYO + RDOS. ESPAÑA Y EUROPA 1T’24. PREVIEWS (ANÁLIS...

COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: ACS, COLONIAL, FERROVIAL, GRIFOLS, LOGISTA, NH HOTELES, UNICAJA. EUROPA: BAYER. Incluido en el informe diario de hoy, y durante toda la campaña de resultados, incorporamos al final una presentación con los resultados destacados en positivo y negativo y previews de Rdos. 1T’24 que se publicarán en España y Europa en los próximos días. Jornada de transición en las bolsas En una sesión sin referencias macroeconómicas y con la campaña de resultados com...

Thomas J. Schiessle
  • Thomas J. Schiessle

Inventory reduction in China completed - guidance FY24 confirmed - gro...

Costs are under control, but an increase in sales in H2/FY 24 is necessary to achieve the bottom line of guidance FY24, which is now qualified as "ambitious". Once there is more clarity on this, the guidance will be specified. The guidance FY24will now only be raised by the D.O.R.C. top-line contribution (FY24: approx. € 100m; D.O.R.C. bottom-line contributions (incl. ppa) will follow later).

 PRESS RELEASE

Transactions in Connection with Share Buy-back Program

Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; May 13, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares.The share buy-back program is expected to be completed no later than December 16, 2024. The following transactions were executed under the program from May 6, 2024 to May 10, 2024:  Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)Accumulated through last announcement 689,510 1,393,154,997.08May 6, 2...

Thomas J. Schiessle
  • Thomas J. Schiessle

Lagerabbau in China abgeschlossen - 24er Guidance betätigt - Wachstums...

Die Kosten sind im Griff, doch ist eine Umsatzausweitung im H2/FY 24 nötig, um die inzwischen als „ambitioniert“ qualifizierte bottom-line der Guidance 24 zu erreichen. Wenn hierüber mehr Klarheit herrscht, wird die 24er Guidance konkretisiert werden. Die 24er Guidance wird jetzt nur um den D.O.R.C.-Topline-Beitrag (FY 24: ca. € 100 Mio.) angehoben (D.O.R.C.-Bottomline-Beiträge (inkl. ppa) folgen später).

Carole Braudeau
  • Carole Braudeau

Credit Morning 05/08/2024

Stada : Reportedly potential IPO in Q3 24Continental / Q1 24 results: Weak set of results subject to volume losses and labour inflationCrédit Logement published FY 2023 annual resultsBanco BPM published strong Q1 results>...

Carole Braudeau
  • Carole Braudeau

Morning Crédit 08/05/2024

Crédit Logement publie ses résultats annuels 2023Banco BPM publie de solides résultats trimestriels Continental / Q1 24 results: Weak set of results subject to volume losses and labour inflation Stada : Reportedly potential IPO in Q3 24>...

Oliver Metzger
  • Oliver Metzger

Carl Zeiss Meditec : Q2 review – Miss on top line and adj. EBIT

>Q2 review – miss on top line and adj. EBIT - Q2 2024 revenues € 472.1m (-6.4% y-o-y) were driven by a constant currency decline of c. 0.7% and a forex headwind of 570bp, or -7%/-7% vs ODDO BHF/consensus. EBIT of € 64.7m (-22.7% y-o-y, margin 13.7%) was 11%/17% ahead of expectations pushed by Topcon settlement. Adj. EBIT reached € 49.0m (-43.2% y-o-y, margin 10.4%) and was -3%/-13% vs consensus. EPS of € 0.52 compares to expectations of € 0.49 and € 0.46 for the conse...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch